Medika Life has covered the halls of JPMorgan in San Francisco, ViVE in Nashville, and the Digital Health Summit in Boston. But the outreach received before BIO—from stakeholders in Austin, Belfast, Milan, Riyadh, and Tulsa—suggested something seismic was shifting. At BIO 2025, that story came into focus: a world where health innovation is no longer limited by geography but defined by vision, investment and intention.

The Biotechnology Innovation Organization isn’t just where technologies are launched and global biotech identities are shaped. What we witnessed in Boston this year wasn’t just presence, but purpose. From Riyadh to Milan, leaders arrived not merely to exhibit, but to engage. They came to say, ‘We are here. We are investing. We are innovating.’ BIO 2025 stood out for its sheer scale and energy—a mosaic of emerging voices ready to help steer the next wave of life science breakthroughs.

Global Trends: Infrastructure, Incentives and Inclusion Drive Expansion

A common thread across these rising biotech regions is the power of public-sector catalysts. Investment in R&D tax credits, translational research centers, and workforce training has de-risked innovation for early-stage companies. Regions like Oklahoma and Northern Ireland exemplify how government partnerships with academia and industry can create a vibrant life sciences pipeline.

In parallel, digital innovation is enabling smaller regions to leapfrog traditional limitations. AI-led discovery, digital twins, and virtual trial platforms are reducing costs and increasing speed-to-data. This convergence of science and software is helping new hubs like Austin and Riyadh accelerate globally competitive capabilities in diagnostics, personalized medicine, and regulatory science.

“We’re not competing with Boston—we’re complementing it,” said a delegate from Invest Northern Ireland. “In a connected world, biotech ecosystems aren’t isolated—they’re collaborative nodes on a global grid.”

Meanwhile, leaders from Italy’s Ministry for Foreign Affairs and Saudi Arabia’s SFDA emphasized the importance of regulatory agility. Their message was clear: modern biotech requires modern policy. Whether through centralized ethics boards, digital review platforms, or alignment with international standards, regulatory transformation is essential to scale innovation.

These developments signal a broader inflection point—biotech is no longer about place. It’s about purpose, policy, and partnerships.

Austin: Where Tech Meets Translational Medicine

Austin is no longer just the city of live music and digital startups. With more than 300 life science companies and a 74% employment boom in biotech over the past five years, it’s transforming into a powerhouse of translational medicine.

Heavyweights like Thermo Fisher, Natera, and Luminex now call Austin home, joined by trailblazers such as Paradromics, Elligo Health Research, and Prophase Biostudios. These companies blend biotech, medtech, and AI in ways that are shaping the next frontier in diagnostics, therapeutics, and digital health.

“As one of the country’s fastest-growing emerging life sciences hubs, the Austin region is responsible for a significant portion of the biotechnology sector’s growth in Texas,” said Ed Latson, CEO of Opportunity Austin. “Our tech talent, VC ecosystem, and institutions like UT Austin are driving an uptick in innovations, with over 350 life science patents issued to Austin companies in the past five years.”

Austin’s 4.4 million square feet of science innovation space—plus another 1.1 million square feet under construction—signals that this rise is more than momentum. It’s movement.

Italy: From Scientific Legacy to Global Scale

Italy’s BIO 2025 pavilion was both a showcase and a statement: this country is stepping into biotech leadership. Long known for its academic excellence, Italy is now connecting its research infrastructure to industrial manufacturing and global markets.

With 770 production sites and the largest Contract Development and Manufacturing Organization output in Europe (€3.6B), Italy is scaling up innovation across oncology, AI diagnostics, and organ-on-chip development. Companies like BiomimX, Math Biology, Genenta Science, and InSilicoTrials are bridging cutting-edge science with clinical utility.

“Italy’s presence at BIO Boston reflects years of work by the Italian Trade Agency to promote an integrated system of scientific expertise, high-tech supply chains, and a talent-rich ecosystem,” shared Erica Di Giovancarlo, Director of the ITA New York Office.

Initiatives like the Montalcini Global Biotech Tour and policy instruments from the Ministry for Foreign Affairs support this ambition.

“Pharma is one of Italy’s top global exports,” noted Mauro Battocchi, Director General. “That would be unthinkable without a strong base in R&D, regulation, and manufacturing.”

Northern Ireland: Precision Science with Global Reach

With 250+ companies and $2.5 billion in revenue, Northern Ireland’s life sciences sector has grown 75% in just three years. The delegation to BIO was led by Invest Northern Ireland and featured companies from drug discovery (AMPLY), CRO services (Almac, Celerion), and diagnostics (Randox).

Queen’s University Belfast and Ulster University deeply anchored the region’s ecosystem. Global companies are noting that Celerion recently relocated its UK Phase I operations to Belfast’s new iREACH facility, betting on local talent and translational research capacity.

From scientific rigor to export capability—145+ countries and counting—Northern Ireland proves that locale doesn’t limit global vision.

Oklahoma: Equity-Focused Innovation with Local Roots

Oklahoma’s biotech renaissance is rooted in intentionality—it is focused on equity, local workforce development, and community-based innovation. Biosciences now contributes more than $16 billion to the state’s economic impact, with more than 750 companies and 42,000 jobs.

The Oklahoma delegation at BIO emphasized sustainability, manufacturing, and health equity, with standout organizations including Wheeler Bio, BioTC, ParaNano, and Utopia Plastix.

“We’re not here to be a branch office,” one delegate told me. “We’re here to bring Oklahoma’s soul to the bioscience table.”

With significant support from the Oklahoma Center for the Advancement of Science & Technology (OCAST), OKBioStart, and the University of Oklahoma, this state is redefining what it means to be an innovation hub.

Saudi Arabia: A New Powerhouse for Biotech Partnerships

Saudi Arabia came to BIO with a clear strategy and global ambitions. Led by His Excellency Prof. Dr. Hisham Saad Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), the Kingdom made its voice heard across two key sessions.

At “Global Biotechnology at a Crossroads,” Dr. Aljadhey discussed Saudi Arabia’s modernization of clinical trials and regulatory frameworks, aligning with international standards. At “Partnering for Progress,” he showcased the Kingdom’s integrated biotech ecosystem, spanning R&D, data, manufacturing, and patient care.

Beyond BIO, the SFDA delegation engaged with Harvard University and global pharmaceutical leaders and joined a private sector roundtable hosted by BIO and the U.S. Chamber of Commerce. These engagements reflect Saudi Arabia’s commitment to cross-border collaboration, secure supply chains, and sustainable innovation infrastructure.

With leaders from the Saudi Ministry of Health, King Faisal Specialist Hospital, and the National Institute of Health also in attendance, the message was clear: Saudi Arabia is ready to be a regional biotech hub with global reach.

The New Map of Global Innovation

This isn’t just a reshuffling of zip codes. It’s a redrawing of the innovation map—pushed forward by ecosystems committed to inclusion, science, sustainability, and scale.

These five rising regions aren’t simply showing up. They’re standing up—challenging legacy thinking, collapsing silos, and reminding the world that leadership in life sciences doesn’t require a familiar address. It requires ambition, alignment, and action.

At BIO 2025, the message was unmistakable: where you innovate matters less than why you innovate—and for whom.

From Austin’s AI-powered translational medicine to Saudi Arabia’s regulatory reinvention, the next wave of breakthroughs will be shaped not by old borders but bold commitments.

Expectations are high. Patients in Milan and Muskogee, Belfast and Boston, Riyadh and Rochester are not waiting for innovation to trickle down. They are looking globally—for the fastest path to solutions that sustain and save lives.

The future of biotech is already in motion. It’s inclusive. It’s intentional. And it’s unstoppable.

The post BIO – Biotech Without Borders  appeared first on Medika Life.

The FemTech Foundation—and Fault Lines

In 2015, fewer than 300 ventures focused on women’s health existed. That number has tripled to 942, according to the Galen Growth HealthTech Alpha™ platform. These ventures now span the female health continuum—gynecology, menopause, oncology, cardiovascular disease, mental health and beyond.

Yet the investment tide has not fully turned in FemTech’s favor. While partnerships have risen 15.3-fold during the past decade, capital deployment has grown only 1.4 times. Compare that to the 2.6x expansion of digital health investments. In 2024, FemTech secured $2.2 billion in funding, a sliver of the $26 billion digital-health pie.

This disparity isn’t due to a lack of innovation—quite the opposite. The problem is systemic: funding gaps, policy voids, and clinical blind spots that overlook the $360 billion “ghost market” of women’s health. That phrase— “ghost market”—is the report’s haunting term for the opportunities left untouched by current investors and providers alike.

From Fertility to Full Spectrum

One of the report’s most critical takeaways is how much the FemTech category is maturing. Fertility tracking and pregnancy apps put the field on the map. But FemTech today is far more.  It recognizes the vast need for medicine to engage with women’s unique health needs, long unaddressed.

The Galen Growth data shows that while gynecology and oncology account for more than half of all FemTech ventures, menopause, chronic pain, autoimmune conditions, cardiovascular disease and mental health are surging into the investment and innovation spotlight. These are not “niche” categories—they represent common, often underdiagnosed or misdiagnosed conditions that disproportionately affect women and impair their quality of life.

This expansion reflects a growing recognition that women’s health is not a subset—it’s a central pillar of public health. As de Salaberry writes in a soon-to-appear Health Tech World byline: “To be transformative, FemTech must address the entirety of the women’s health continuum, including those therapeutic areas that are not traditionally branded as female-specific but affect women in distinct ways.”

Twice the Clinical Evidence—But Still Under Scrutiny

Perhaps the report’s most sobering—and telling—data point is that FemTech ventures generate nearly twice the volume of clinical trials, peer-reviewed research, and regulatory filings as their digital health peers. Twice. That’s not due to past scientific rigor; these companies are held to a higher standard. Founders and advocates must go the extra mile to validate the clinical value of their solutions.

Despite this, systemic barriers remain. The report shows 71 percent of early-stage FemTech ventures struggle to raise a Series A round. Funding the “middle”—those post-seed but pre-scaleup companies—is an urgent priority. Without it, too many promising solutions will stall before reaching the women who need them.

Let’s be clear: this isn’t just about meeting investor milestones. It’s about delivering equity in care. Cardiovascular disease is the leading cause of death among women, yet it remains underrepresented in FemTech portfolios. Alzheimer’s and autoimmune conditions disproportionately affect women, yet receive comparatively little innovation focus.

Those are not oversight gaps. They are deep, systemic failures – disparities in our health innovation system.

From Direct-to-Consumer to Deep Health Integration

Another significant signal of maturity is the shift away from pure direct-to-consumer (DTC) models. In 2024, 42 percent of FemTech partnerships involved health systems, up from just 10 percent in 2020. That’s a tectonic shift from point solutions to systemic integration.

As de Salaberry puts it, “DTC strategies alone cannot reach underserved populations or secure the reimbursement pathways necessary for scale.” Systemic integration—through payers, providers, and public institutions—is essential for sustainability and access. FemTech must live where care happens, not just on consumers’ cell phones.

Regionally, the picture is just as telling, with Europe leading in clinical rigor, with 50 percent of FemTech ventures demonstrating proven clinical strength. North America leads in funding ($1.3B), while Asia-Pacific remains a hub of AI-driven diagnostics, even amid a dip in capital investment. These trends point to what’s next: a future driven by localization, clinical excellence and technology convergence.

Forces Shaping the Future of FemTech

The report outlines five key factors shaping the FemTech evolution during the next five years. They’re worth noting for anyone investing, innovating or advocating for equitable care with an eye toward return on investment:

• Redefining the Scope: FemTech must look beyond reproductive health to address chronic diseases, aging, and behavioral health.
• Breaking the DTC Mold: Success will be defined by integrated partnerships with employers, insurers, and health systems.
• Balancing Rigor and Agility: Regulatory requirements must support innovation without stifling it.
• Funding the Growth Gap: Series A and B support is critical to help early innovators scale.
• Smart Consolidation: M&A isn’t just about exits—it’s about building category leaders with breadth and credibility.

Infrastructure, Not Hype

The key here is infrastructure. FemTech is not a trend—it’s the scaffolding of women’s health innovation. Investors need to hear that message and invest to make this population health category viable.

With nearly half the global workforce made up of women, the ROI on women’s health is not just moral—it’s macroeconomic. The health ecosystem can no longer afford to treat women’s health as an edge case. It is, in fact, the core of population health.

FemTech’s next chapter will be shaped by evidence, equity and integration. It must also be underpinned by trust from payers, providers, and patients. That trust is earned through data, outcomes and the bold assertion that women’s health is health, full stop. This Galen Growth Report goes a long way to demonstrating the positive outcomes when innovation and investment converge.

As Julien de Salaberry wisely states: “The next generation of Femtech isn’t about visibility—it’s about value, integration, and health systems impact.” That’s not just a forecast—it’s a framework for what’s next.

[Editor’s Note: For a deeper dive into the Galen Growth FemTech 2025 report, visit galengrowth.com. The full report and press release, are available now.]

The post Galen Growth FemTech 2.0 Report: Elevating Women’s Health from Niche to Necessity appeared first on Medika Life.

Imagine it’s the mid-1990s and the U.S. has decided to pursue policies that would restrict trade and investment to Asia instead of promoting it. Would those markets still prosper? Would the U.S. have grown as strongly or had the same counterweight to China if the American government had abandoned Indonesia, Vietnam, Thailand, Malaysia, Singapore or other regional markets?

At the time, these countries represented the next frontier of economic opportunity for American companies seeking to establish manufacturing and financial hubs, sell to millions of new consumers and tap an emerging talent base. Much of the economic data from the past thirty years underscores the mutual economic benefits that came from favorable policies that promoted deeper diplomatic cooperation and corporate investment in Asia.

I had a front row seat on this economic rocket ride early in my career, spending more than four years right after college working in international marketing throughout Southeast Asia. We have seen a tectonic shift in global trade since then, mostly resulting in incalculable benefits to global trading partners, including the U.S., as market access has opened for an array of goods and services. In combination with health systems investments, countries like Indonesia, which were once leading recipients of development assistance, have seen their GDPs increase to the point where they are now considered middle-income countries and are providing economic assistance to other countries in public health programs like the ones supported by Gavi, the Vaccine Alliance.

This sort of massive transformation came about because the U.S. and other countries played the long game. It’s crucial to keep this in mind – and the hypothetical scenario of where we would be today if we had lopped off trade opportunities with Asia 30 years ago – because we are about to retreat from the next great frontier market of the 21st century: Africa.

The implications of such a move are reflected in economic and demographic data. Eleven out of the top 30 fastest-growing economies in the world last year were in Africa. A staggering 70 percent of the population is under 30 years old, a tsunami of innovators, entrepreneurs, researchers and everyday workers hungry to supercharge their futures. In health, education, financial services, technology, manufacturing and many other sectors, African markets are showcasing new models that can help emerging economies leapfrog in their economic development.

It’s a big reason why China, India, the Gulf States and many other countries are racing to establish economic partnerships with key African markets so they have an established presence as the region becomes more prosperous. But the United States is opting out.

Currently, plans developed by the Trump Administration to reorganize the State Department indicate an intention to scale back the American diplomatic presence substantially in Africa. This follows the dismantlement of USAID, de-funding of PEPFAR and other key public health programs, and the anticipated scuttling of the Africa Growth and Opportunity Act (AGOA), a vital trade agreement that allows for duty-free access to the U.S. for many African exports.

The result of these cuts could leave the U.S. government and companies sidelined from any meaningful diplomatic engagement and commercial gains as African markets race ahead with support from our greatest geopolitical rivals. Without robust engagement from American embassies, U.S. companies may be hobbled as they seek to create commercial partnerships, understand the competitive landscape of key African markets, negotiate regulatory barriers and navigate legal and operational threats that arise in any market.

Such a shutout may be felt acutely by American biopharmaceutical companies and health start-ups that include African markets in their clinical trials, partner with national governments and civil service organizations on early-market initiatives, attract talented scientists and build brand loyalty with more than a billion new health consumers. Policy and regulatory issues in Africa are routine problems that healthcare companies work with American embassies to solve, along with risk management.

Then there is the potential cost to domestic U.S. healthcare from cutting global health programs and diplomatic presence in Africa. USAID offices were often attached to American embassies and have been among the first to respond to the early detection of disease outbreaks. The U.S. spent $900 million in 2023 to fund laboratories and emergency preparedness and response in more than 30 countries, many in Africa. Those programs are now on hold, which increases the danger that outbreaks of polio, Ebola, Marburg, and mpox, as well as bird flu, could erupt. Without that frontline defense, the risks grow dramatically higher for existing and new diseases to reach Americans at home and overwhelm our health systems.

It’s become cliché to say “health there affects health everywhere,” but when more than 77 million people travel to the U.S. from foreign destinations in 2024, it’s obvious that humans are the greatest vector known to disease. America’s massive biomedical research capacity and our biopharma companies are at the vanguard of protecting our health. Abandoning our political and commercial connection to key countries in Africa reverses years of important progress.

We depend on access and cooperation with Africa’s emerging markets to help maintain our health defenses and build a next generation drug pipeline, but also to create a pathway to future economic growth. Without the vital support our companies receive through U.S. diplomatic assistance, that pathway could be closed off. Are we prepared to risk that?

The post Retreating from the Opportunity of a Century appeared first on Medika Life.

Security, Migration, and Budget Pressures

A confluence of political and fiscal forces is accelerating this shift. Europe’s strategic priorities have evolved, driven by concerns ranging from war and migration to domestic economic strains. Many governments feel pressure to divert funds toward defence and security amid Russia’s war in Ukraine and other threats. In Britain, for example, leaders explicitly tied an aid rollback to military needs: Prime Minister Keir Starmer vowed to boost defence spending to 2.5% of GDP and fund it by cutting the aid budget from 0.5% to 0.3% of national income. “National security must always come first,” Starmer said, framing the cut as a painful necessity in a “dangerous new era”.

Curbing immigration is another powerful motivator. Italy’s Prime Minister Giorgia Meloni, elected on a hard-right platform, has bluntly rejected the notion of altruistic aid in favour of deals that keep migrants from leaving Africa. “What needs to be done in Africa is not charity,” she declares. “What needs to be done in Africa is to build cooperation and serious strategic relationships as equals, not predators”. For Rome, that means investing in African infrastructure and economies (dubbed the “Mattei Plan”) to create jobs in migrants’ home countries — and securing Italian energy and business interests — rather than simply writing checks. Other governments in Europe’s north echo this tougher line: the Netherlands’ new ruling coalition plans to trim aid by 2029 while “prioritising the interests of the Netherlands,” shifting funds toward domestic migration control and trade promotion.

At the same time, budget constraints and surging nationalist politics have made foreign aid a prime target for cuts. The populist refrain of “charity begins at home” has grown louder amid economic uncertainty, pandemic debts, and inflation. Even in France — historically a champion of development aid — the government quietly backtracked on a legally enshrined promise to reach the U.N.’s 0.7% aid spending target by 2025. Facing pressure to reduce deficits, President Emmanuel Macron’s administration postponed the 0.7% goal to 2030 and slashed next year’s aid budget by over one-third. A €742 million reduction in 2024 was followed by plans for a further 37% cut (more than €2 billion) in 2025. Such steep cuts, unprecedented in modern French policy, were justified as tough choices in a tight fiscal environment — though critics called it a betrayal of France’s global commitments. Likewise, aid has been swept up in a broader fiscal odyssey in Germany. After a constitutional court ruling forced Berlin to reallocate spending, the development ministry’s 2024 budget was pared down by about 8% (roughly €940 million) compared to the previous year. Germany’s humanitarian relief budget also dropped about 10%. These reductions make it unlikely Germany will maintain its recent 0.7% GNI aid level.

European Aid Budgets in Retreat

The result of these pressures is a marked pullback in many European aid budgets — a trend that spans both EU member states and neighbours like the UK and Switzerland. Recent moves include:

• United Kingdom — Once a leader in aid, the UK has reversed course. It first lowered its long-held 0.7% of GNI aid commitment to 0.5% in 2021 and now plans to sink to just 0.3% by 2027 to free up billions for defence. Aid groups warn this will drag UK assistance to its lowest share of national income in generations, a “short-sighted and appalling move” that will “undoubtedly risk lives,” according to UNICEF.
• France — After years of incremental increases, France is making an abrupt U-turn. The 2025 budget envisions a 35% cut in official development assistance, delaying ambitions to scale up programmes. Lawmakers in Paris concede domestic needs and security priorities are eclipsing foreign aid — a stark change for the world’s fourth-largest donor, which in 2023 still spent €13.9 billion (0.48% of GNI) on development.
• Germany — The eurozone’s largest economy is trimming aid amid belt-tightening. Germany’s 2024 federal budget reduced core development spending to €11.2 billion, about 7–8% lower than in 2023. Humanitarian and crisis aid saw even sharper declines. Further cuts are on the table for 2025 as Berlin prioritises energy price relief and defence.
• Belgium — A new coalition government in Brussels has agreed to cut development cooperation funding by 25% over five years. Belgium’s aid agency has sounded the alarm, with Enabel CEO Jean Van Wetter warning that “disinvestment in international cooperation is a poor decision in our interconnected world” and will undermine Belgium’s global influence.
• Switzerland — Historically, Switzerland has been a steady donor, but the Swiss government is also scaling back. It approved a CHF 110 million reduction in its aid budget and plans to shut down or hand off development programmes in at least three countries (Albania, Bangladesh, and Zambia) by 2028. Swiss officials argue that resources must be focused on fewer priorities as part of a wider cost-cutting drive.
• Italy — Italy’s aid budget has not seen dramatic cuts, but its focus has pivoted under Meloni’s leadership. Rome is redirecting funds toward projects that dovetail with Italy’s geopolitical agenda — chiefly stemming migration. Italian ministers talk of “investment, not charity” and have struck deals, for instance, to finance development projects in Tunisia in exchange for cooperation on keeping migrants from crossing the Mediterranean.

Notably, this contraction is Europe-wide. A recent review tallied seven European donor governments announcing major aid reductions or reallocations in the past year. The collective EU aid effort is sliding: EU institutions and member states gave 0.51% of GNI as aid in 2023, down from 0.56% the year before. In a mid-2024 budget review, the EU reallocated €2 billion of its external aid fund into migration and refugee support — effectively a 7.5% pro-rata cut to other development programmes. As one analyst bluntly summed up, “The door is just closing on aid everywhere we look.”

From Grants to “Blended” Finance

Beyond budget cuts, Europe is fundamentally changing how it delivers whatever aid remains. Rather than simply funding government budgets or health clinics in poor countries, European donors are channelling money into financial instruments — loans, equity stakes, guarantees — that attract co-investors and, ideally, pay for themselves. The buzzword is “blended finance,” which means using a small amount of public or aid money to unlock a larger pool of private capital for development projects. In theory, everyone wins: poor countries get more investment than aid alone could provide, while investors (including European development banks) get risk cushioned by public funds.

All across Europe, aid agencies have been refashioned as mini-development banks. The UK’s famous aid department has been folded into the Foreign Office, and its once grant-focused bilateral programmes are diminished. Instead, Britain is leaning on British International Investment — a government-owned DFI (development finance institution) — to finance projects from renewable energy in India to tech start-ups in Africa, expecting modest returns. France’s Agence Française de Développement (AFD) has likewise expanded its lending, often via its private-sector arm Proparco, under what President Macron calls a “policy of results” approach. “The ambition of this strategic plan is [for AFD] to become a platform for development policy,” Rémy Rioux has said, describing AFD’s evolution beyond traditional aid. AFD now provides billions in low-interest loans for infrastructure and climate programmes, blending French funds with multilateral and private money.

Germany’s KfW Development Bank and its investment subsidiary DEG follow a similar model, financing everything from solar parks to microfinance institutions in developing markets. Even smaller donors have set up investment vehicles — Switzerland’s SIFEM fund, for instance, takes equity stakes in emerging market SMEs. Increasingly, European aid is less about writing checks than structuring deals. As Rioux explains, “Development financing is undergoing a major transformation… Investment has another advantage: it’s built for the long term. It creates lasting partnerships, allows us to track tangible impacts, and demonstrates returns… far more effective and convincing than traditional public aid”. In his view, and that of many peers, mobilising “sustainable resources” through investment is the only way to meet 21st-century challenges as government grants stagnate.

Critically, Europe’s new approach isn’t just about altruism — it’s about mutual gain. Donor governments are so unabashed that they expect strategic payoffs. “International cooperation is not just an act of global solidarity,” says Enabel chief Jean Van Wetter, whose Belgian agency increasingly ties aid to domestic interests. “It is a strategic investment that will bring numerous benefits to Belgium, its businesses and its citizens… By encouraging stability, growth and sustainability in partner countries, Belgium strengthens its own security, economy and international reputation”. This “good for them, good for us” philosophy now permeates European development strategy. Nowhere is it clearer than the European Union’s flagship Global Gateway initiative — a €300 billion plan unveiled in 2021 to fund infrastructure in Africa, Asia, and Latin America. Billed as Europe’s answer to China’s Belt and Road, Global Gateway explicitly seeks “mutually beneficial partnerships” that serve development needs and boost the EU’s strategic autonomy. Projects range from African internet connectivity (benefiting EU telecom firms) to renewable energy grids that could one day supply Europe. “We are moving away from traditional development to mutually beneficial partnerships,” the EU’s development commissioner’s office said, underscoring that the old donor-recipient dynamic is being replaced with joint ventures.

Ripple Effects on Poor Countries

Europe’s pivot has profound implications for countries on the receiving end. In the short term, budget cuts are already being felt in vulnerable communities. Programmes that tackle poverty and disease — but yield no financial return — face an uncertain future. Global health initiatives, in particular, are reeling. Several of Europe’s biggest aid donors have been mainstays of funding for vaccines, HIV treatment, and health systems in Africa. Now, those budgets are shrinking just as need remains high. “Some of Europe’s biggest global health funders are slashing their aid budgets, which health groups fear could spell catastrophe for countries reliant on foreign cash to combat malaria, HIV, tuberculosis,” reports Euronews. Because Europeans are turning inward, health programmes that saved millions of lives may lose support. In 2023, about 10% of European ODA went to global health. Still, going forward, that share must compete with climate projects and private-sector loans for a “shrinking pot of money”. “Many lives are at stake,” warns Dr Michael Charles, head of a major anti-malaria partnership, describing the situation as “quite dire” in countries where donor-backed health services are now at risk.

Lower-income countries could also struggle to attract the kind of private investment Europe is now favouring. The pivot to loans and equity tends to favour middle-income states or commercially viable ventures — where investors see a reasonable chance of returns. Poorer nations, or social sectors like basic education, may be left behind because they offer little profit. Aid advocates note that European funds are flowing increasingly to regions of strategic interest (for example, North Africa for migration control or Ukraine, which alone absorbed nearly €19 billion of EU institutions’ aid in 2023 (Donor Profile: EUI)). Meanwhile, the share going to the least-developed countries has been “trending downward since 2017”. If this continues, the world’s poorest countries may face a double blow: less grant money and limited access to investment capital. Those who do take on more loans could risk new debt burdens down the line. “We have to ensure no one is left behind as we shift to finance and investment,” cautions one development official, noting that purely market-driven aid could bypass fragile states that need help most.

On the other hand, some developing nation leaders welcome the rhetoric of partnership over patronage. African governments have long bristled at the demeaning connotations of “aid” and have called for “trade, not aid” for decades. They see opportunity in Europe’s investment pivot — if it delivers real infrastructure and business growth. In their view, being treated as an investment destination, not a charity case, is a step toward equality. However, they also emphasise that partnerships must be genuine. At a recent EU-Africa forum, several African presidents pointedly rejected mere “EU charity”, saying Europe should address structural imbalances in trade and invest in African value chains rather than offer handouts as a way to buy political favours. In practice, the jury is still out on whether Europe’s new model will benefit developing nations or mainly serve Europe’s interests.

A New Hybrid Model — End of Aid as We Know It?

Is this the end of traditional aid? In many respects, yes. Europe’s development assistance is becoming inseparable from its economic and geopolitical strategy. Whereas 20th-century aid often aimed to foster development for its own sake — rooted in post-colonial moral duty or Cold War diplomacy — 21st-century aid from Europe is increasingly transactional. Grants with no strings attached give way to loans, equity investments, and deals tied to policy conditions (migration management, economic reforms, climate goals). The old model of wealthy nations simply donating money is fading. “The old model of public development aid is disappearing and must be replaced by sustainable and inclusive investment,” says AFD’s Rémy Rioux, who argues that virtually all stakeholders now “agree that we need to rethink the model”. European officials often bristle at the word “aid” altogether. They prefer terms like “cooperation,” “partnership,” and “investment.”

Yet this is not so much an end as an evolution into a hybrid model. Europe isn’t abandoning poorer countries; it is just engaging on different terms. In place of one-way charity, it envisions joint ventures — what one Belgian policy paper calls “reciprocity-based development”. Even as budgets tighten, Europe is leveraging other tools to stay involved abroad: development banks, venture funds, risk guarantees, and diplomatic agreements linking aid to trade. In effect, official development assistance is blended with foreign and commercial policies. It’s no coincidence that the UK merged its aid agency into its diplomatic service or that the EU’s development projects now fall under a strategy explicitly tied to European industrial and security interests. As the European Council concluded its next budget, the goal is to “ensure the [aid] budget advances the EU’s strategic priorities, which are increasingly shaped by domestic interests such as competitiveness, access to raw materials, migration, and security.” This signals a permanent change in mindset.

Whether this new approach can deliver positive results for developing nations remains an open question. Optimists argue that by making development cooperation more about business and mutual gain, Europe will sustain political support and unlock larger pools of money than stagnant aid budgets could. They point to initiatives like Global Gateway and say that if Europe invests smartly in emerging economies, it can help build sustainable industries (from African solar farms to Southeast Asian supply chains) that benefit everyone. Sceptics, however, worry that something fundamental is lost when self-interest justifies aid. There are fears that vital but unprofitable work — fighting extreme poverty, tackling malnutrition, bolstering primary healthcare — will fall by the wayside. They note that global pandemics or climate change require outright grants and global solidarity, not investments that expect a financial return.

European officials insist they are not retreating from global development, just modernising their approach. “France is not stepping back from its international role,” Rioux insists, citing Europe’s $150 billion collective development contribution — roughly three times the U.S. level. But he and others acknowledge the need to “build a more resilient and efficient model” that can withstand domestic political winds. That model increasingly blurs the line between aid and business. It treats poorer countries less as beneficiaries and more as partners — or, in some cases, markets. The Wall Street Journal once dubbed this trend “aid as investment”, and today it’s an apt description of Europe’s new paradigm. Traditional aid may not be entirely dead, but it has undeniably been subsumed into a broader strategy of strategic partnerships.

As Europe resets its development playbook, the world is watching to see if this grand experiment produces genuine development — or if “mutual benefit” mostly benefits the donor. For millions in Africa, Asia, and beyond who have depended on European aid, the hope is that this new era will bring a different rhetoric and tangible progress. If Europe’s investments can drive growth and stability in poorer nations while satisfying European taxpayers, it could herald a new global development model for the 21st century. If not, retreating from traditional aid could leave a void that other powers — or crises — will fill. The only certainty is that Europe’s role in international development is changing profoundly, in real-time, trading in the old charity mindset for something more hard-nosed and, it believes, sustainable for the long haul.

The post Europe Reimagines Foreign Aid as Investment appeared first on Medika Life.

It’s frustrating, but setbacks often come with silver linings. There’s always next season, another chance to try the restaurant, or new prospects waiting on the horizon.

But what happens when the stakes are higher? When the failure to achieve a critical goal means more than a personal letdown — it threatens the very foundation of your work?

Imagine your technology fails to get the certification needed to hit the market, putting your startup’s survival in jeopardy. Or the policy you’d counted on to support your market entry doesn’t pass, leaving you to face an uphill battle.

Or, how about the world’s biggest economy pulling back from collective climate action?

Facing a New Reality

For innovators around the globe, the shifting priorities of the US Federal government vis-à-vis climate action struck a blow. Policies like withdrawing from the Paris Agreement (again), reducing investments in clean energy infrastructure, and pivoting back to fossil fuels have left many in the climate sector on edge.

But these challenges are a call for resilience and persistence. For the climate tech sector, this isn’t just about political setbacks — it’s about reimagining its role in a world where change is constant, risks are high, and opportunities are emerging in unexpected places.

The question isn’t whether climate action will continue; it’s about who will lead it and where innovation can make the greatest impact.

We are entering a new reality. Whether that reality is good or bad is a matter or perspective and priorities — completely subjective.

What is clear is that the world is facing new challenges related to climate –more destructive and unpredictable wildfires, increased desertification, more plastic littering the environment and entering our food systems and our bodies, and biodiversity at risk from all manner of pollution. Our natural ecosystems are out of balance and we see the impact — wildfires, floods and excessive heat.

To put it differently, we are faced with a serious set of unmet needs. And when there are unmet needs, there is an opportunity for innovation. And very few do innovation better than Israel — a testing ground for climate innovations for decades.

Global Climate Action Will Continue to Set the Course

Even as the US Federal government reconsiders its role in global climate action, the momentum hasn’t stopped. Instead, leadership has diversified. States, nations, corporations and individuals are stepping up, creating a dynamic environment where businesses must adapt and pivot to new opportunities.

For instance, The United States Climate Alliance — a group of 24 bi-partisan governors representing 60% of the US economy, have made clear that climate action will continue in the United States, albeit, state-led. Former mayor of New York City, and billionaire philanthropist Michael Bloomberg, has committed, together with other US climate donors, to help cover the United States’ financial commitments to the United Nations Framework Convention on Climate Change.

The US Isn’t the Only Player in the Game

The European Union continues to exhibit strong leadership in transitioning its economy. Policies including the Carbon Border Adjustment Mechanism (CBAM) and the EU’s Green Deal will put Europe on track to be the first climate-neutral continent by 2050.

China has become a world leader in solar energy, and a leading producer of wind turbines and electric vehicles, driving the global shift to clean energy. The country is investing in its green infrastructure, aiming to reach carbon neutrality by 2060.

For climate innovators in general, and Israeli entrepreneurs specifically, understanding how to do business in these markets will be essential in the coming years. Climatetech companies should dedicate some resources to understanding these markets of opportunity.

The Resilience of Climate Investors: US, EU and Israel

Despite some big players pulling back, and investment in climate tech trending down, many investors see the sector as a critical component of a diverse portfolio, not just because it’s good for the planet, but because it makes business sense.

The overall climate investment ecosystem is strong. Breakthrough Energy Venture, founded by Bill Gates, has not slowed on its commitment to reach Net Zero by 2050, raising an $839M fund in August 2024. AllianzGI and the European Investment Bank just raised €450M for climate action in emerging markets. A slew of early-stage VCs are ready to invest in the next climate dream.

Israeli investors, too, have shown confidence in the climatetech sector, backing technologies that promise to reshape the future of climate action. Firms like Ibex Investors, E44 Ventures, Jibe Ventures, and iKare Innovation continue to invest in new climatetech solutions in clean energy, sustainable farming, carbon capture and water conservation, from early-stage through scale-up and beyond, demonstrating a commitment to both financial returns and global environmental impact.

These Israeli investors are helping bridge the gap between innovation and global markets, positioning Israel as a leader in climatetech solutions, even as some US-based companies face increasing political and regulatory uncertainty.

Why We Need to Double Down on ClimateTech Investment

No matter who is in power, people still need access to clean water, healthy and sustainable food sources, clean air, and safely manufactured products. It’s not only the health of the planet that is at stake but human health as well.

Moreover, unlike solutions of the clean tech past that carried too high a “green premium,” today’s climatetech players understand that to make it, they must have a bullet proof business case. They have to be competitive with the conventional, overwhelmingly fit with existing infrastructures, and as much as possible, not ask people to change their behavior too much, at least in the short term.

The Role of Communications in Navigating Today’s Market

Amid the maelstrom of shifting political, economic, and regulatory conditions, resilience isn’t just about innovation — it’s about effective storytelling. Climatetech companies must do more than develop cutting-edge solutions; they must connect these innovations to the world’s most pressing challenges in a way that inspires action and outline societal and economic value.

Communication is the bridge that connects innovators with investors, policymakers, and communities. It’s what transforms a technology into a must-have solution and builds the trust needed to secure partnerships, investments, and market adoption.

The narrative must be bold, credible, and universal — showing how technology addresses unmet needs, meets the moment of climate urgency, and drives systemic change. By crafting and sharing compelling stories, climatetech leaders can position themselves not just as participants in the climate movement but as indispensable drivers of its success.

The post When Plans Shift: The High Stakes of Climate Innovation appeared first on Medika Life.

CHICAGO, June 30, 2022 — The Chicago ARC, a new venture collaborative focused on accelerating health equity solutions, has signed Memorandums of Understanding (MOUs) with the University of Chicago Medicine and Sinai Chicago as the organization’s first Founding Healthcare Partners, where they will play a crucial role in directing and piloting new technologies to transform healthcare and improve health equity in Chicago and beyond.

The Chicago ARC was founded on the belief that where you live, work, and play should be positive drivers of your health and how you receive healthcare. Areas of focus and impact for the Chicago ARC include maternal and child health, chronic disease management, rural healthcare, aging in place, behavioral and mental health, and cancer diagnosis.

“We’re creating an innovation community in Chicago centered on the healthcare providers and communities they serve,” said executive director Kate Merton, Ph.D., who previously launched the digital health incubator for Anthem and ran the East coast region of JLABS, J&J Innovations’ science incubator and accelerator lab. “With unprecedented access to and involvement from Healthcare Partners, startups will be able to direct their efforts for the greatest impact and benefit from Partner expertise and clinical networks to test, model and scale new solutions.”

Chicago ARC builds upon the proven ARC model (Accelerate, Redesign, Collaborate) of Sheba Medical Center — a Newsweek Top-10 global hospital — which brings together startups with experienced operators and an extensive healthcare partner network.

“Health systems in Chicago and the Midwest create Sheba’s North American epicenter for bringing global innovation and U.S. healthcare communities together – and the Chicago ARC is bringing that community together in new ways to invite more global investment and innovation,” said Dr. Eyal Zimlichman, chief digital transformation officer and chief innovation officer for Sheba Medical Center. “Now, by combining expertise and market opportunity, Chicago ARC and its Healthcare Partners will catalyze new solutions for some of our biggest healthcare challenges. Sheba Medical Center will share our experience to impact equitable healthcare and benefit from learning together with Chicago-area health systems and the community.”

Areas of Focus for Healthcare Partners

Healthcare Partners will pilot technologies that meet the needs of healthcare professionals and the communities they serve, create a community of learning to connect local and global best practices, and promote collaboration and joint projects. In addition, organizations have prioritized areas for increased focus or additional collaboration.

Kenneth S. Polonsky, MD, Executive Vice President for Medical Affairs and Dean of the Biological Sciences Division at the University of Chicago: “The South Side of Chicago has experienced shrinking health care resources for many years. Partnering with the Chicago ARC creates the dual benefit of identifying and integrating global technologies that meet the needs of our patients and healthcare professionals while enabling the University of Chicago to bring its research and innovation expertise to a local and global community seeking to address health inequities. As a partner, we plan to help enhance and utilize UChicago as a community engagement and collaboration epicenter to understand — and address effectively — the South Side community priorities and needs.”

Dr. Ngozi Ezike, president and CEO, Sinai Chicago: “As the largest private safety-net health system in Illinois, the communities Sinai Chicago serves face some of the city’s most severe systemic barriers and suffer the greatest health inequities. Sinai has a successful track record of working in collaboration with the communities we serve across the South and West Sides of Chicago. Working with the Chicago ARC will support Sinai in scaling our existing programs and resources to further serve our patients equitably and effectively.”

The Chicago ARC also presents significant opportunities for international collaboration, in a model that can be replicated in other U.S. markets. “The work Chicago ARC is undertaking with partners in Israel is an example of how Israel and the United States can share expertise to have a significant impact on the realization of equitable healthcare through innovation and community collaboration,” said Yinam Cohen, Consul General of Israel to the Midwest. “The top research institutions, health systems partners, and providers of Chicago and the Midwest – like those the Chicago ARC is bringing together – present an excellent opportunity for Israeli startups looking to establish and expand their presence in the U.S.” 

About Chicago ARC The Chicago ARC is on a mission to accelerate tomorrow’s healthcare solutions to those in need today. Its venture collaborative provides a trusted U.S. partner for startups, accelerating market entry and growth through matched commercial opportunities, investment, and end-to-end support. The Chicago ARC will be the centerpiece of a $3.8 billion health-focused Bronzeville Lakefront along the scenic shore of Lake Michigan next to downtown Chicago and the largest convention center in the Western Hemisphere. Chicago is the top U.S. city for foreign direct investment, corporate relocations, life science VC funding growth, and female founders. The region is home to over 1,600 life science companies, three tier-1 research institutions, and over 28,000 physicians. For more information, visit https://www.chicagoarc.health/.  

The post UCHICAGO MEDICINE, SINAI JOIN CHICAGO ARC AS HEALTHCARE PARTNERS FOR HEALTH EQUITY INNOVATION appeared first on Medika Life.

Digital Health Interviews: Levi Shapiro and Ellie Hanson on Digital Health in Israel

This new episode of Digital Health, hosted by Ukrainian health innovation leader Alex Koshykov, focuses on the topic of digital health in Israel. Guests are mHealth Israel Founder Levi Shapiro and FINN Partners Partner Ellie Hanson. Together, they discuss the current situation in the digital health market in Israel, how government helps startups in their early stages, and what are the main differences between American and Israeli health systems.

Ellie provides a short intro to a marketing strategy for digital health startups while Levi gave lots of useful tips for startup founders.

The post Digital Health Interviews: Levi Shapiro & Ellie Hanson – Digital Health in Israel appeared first on Medika Life.